Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. lowered its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) by 9.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 3,839,329 shares of the biopharmaceutical company's stock after selling 379,627 shares during the period. Vanguard Group Inc. owned about 7.71% of Theravance Biopharma worth $33,133,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in TBPH. Principal Financial Group Inc. acquired a new stake in shares of Theravance Biopharma during the first quarter worth about $101,000. Acadian Asset Management LLC increased its position in shares of Theravance Biopharma by 51.6% during the first quarter. Acadian Asset Management LLC now owns 8,277 shares of the biopharmaceutical company's stock worth $77,000 after purchasing an additional 2,818 shares in the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Theravance Biopharma by 3.1% during the first quarter. Charles Schwab Investment Management Inc. now owns 402,640 shares of the biopharmaceutical company's stock worth $3,850,000 after purchasing an additional 12,095 shares in the last quarter. UBS Group AG increased its position in shares of Theravance Biopharma by 45.0% during the first quarter. UBS Group AG now owns 3,549 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 1,101 shares in the last quarter. Finally, State Street Corp increased its position in shares of Theravance Biopharma by 13.3% during the first quarter. State Street Corp now owns 1,541,533 shares of the biopharmaceutical company's stock worth $14,737,000 after purchasing an additional 181,331 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Analyst Upgrades and Downgrades

TBPH has been the topic of several recent research reports. Evercore ISI cut Theravance Biopharma from an "outperform" rating to an "inline" rating in a research report on Monday, January 8th. BTIG Research initiated coverage on Theravance Biopharma in a research report on Friday. They issued a "buy" rating and a $21.00 price target on the stock.

Theravance Biopharma Stock Up 7.6 %

TBPH stock traded up $0.68 during trading on Friday, hitting $9.61. The company had a trading volume of 777,062 shares, compared to its average volume of 382,669. The firm has a market cap of $466.66 million, a PE ratio of -10.06 and a beta of 0.36. Theravance Biopharma, Inc. has a 1-year low of $8.21 and a 1-year high of $12.03. The firm has a 50-day moving average price of $8.91 and a 200-day moving average price of $9.63.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.02). Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%. The business had revenue of $17.57 million during the quarter, compared to analysts' expectations of $17.49 million. Sell-side analysts anticipate that Theravance Biopharma, Inc. will post -0.83 earnings per share for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.